Pharma & Biotech Global Week in Review 20 January 2010 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

President Obama reportedly seeks to shorten the data exclusivity period for biologic innovators previously agreed to by House and Senate (Patent Docs) (Holman’s Biotech IP Blog) (Patent Docs) (Patently BIOtech)

FTC releases analysis of pay-for-delay settlements; Renews call for legislation (FDA Law Blog) (Patent Baristas) (Patent Docs)

 
General

Changing the game in pharma patent strategy (IP Think Tank)

Patent Harmony in Europe (IP Think Tank)

More on Wyeth v Kappos (Anticipate This!)

UCB moves to the Delhi High Court against Cipla & IPO (Patentcircle)

Argentina: custom confiscates counterfeit medicines (IP tango)

India: Beejasurs of the Indian seed market (Spicy IP)

IP Border measures concerning goods allegedly infringing Intellectual Property rights – article (IP tango)  

Wisconsin Alumni Research Foundation (WARF) wins appeal in patent battle with Xenon (Technology Transfer Tactics), (IP Licensing Law)

President Obama reportedly seeks to shorten the data exclusivity period for biologic innovators previously agreed to by House and Senate (Patent Docs) (Holman’s Biotech IP Blog) (Patent Docs) (Patently BIOtech)

Obama-ization of the Special 301 Report (Spicy IP)

Misplaced fears in the legislative battle over biotech drugs (Holman’s Biotech IP Blog)

FTC releases analysis of pay-for-delay settlements; Renews call for legislation (FDA Law Blog) (Patent Baristas) (Patent Docs)

Drug label encouraging infringing use shows intent to induce (even if prescribed for non-infringing use) (Patent Baristas)

“Product” in SPC law (JIPLP)

Gene patenting – like peas in a pod (Patent Docs)

Pharma litigation study – generic challenges are many, success few (271 Patent Blog)

Post grant oppositions filed in 2009 (Patentcircle)

AIPR reiterates opposition to Patent Reform Legislation (Patent Docs)

Mexican Supreme Court pharma ruling (IP tango)

 
Products

Concerta (Methylphenidate) – US: Infringement of US Patent following a Paragraph IV certification: Alza Corp. et al. v. Kremers Urban LLC et al. (Patent Docs)

Faslodex (Fulvestrant) – US: Infringement of US Patent following a Paragraph IV certification: AstraZeneca Pharmaceuticals LP et al. v. Teva Parenteral Medicines Inc. et al. (Patent Docs)

Lexapro (Escitalopram) – Australia: High Court refuses special leave concerning enantiomer patents HLundbeck A/S v Alphapharm Pty Ltd (IP Whiteboard)

LoSeasonique (Ethinyl Estradiol) –Infringement of US Patent following a Paragraph IV certification: Teva Women’s Health, Inc. v. Lupin, Ltd. et al. (Patent Docs)

Lumigan (Bimatoprost) – US: Infringement of US Patent following a Paragraph IV certification: Allergan Inc. v. Sandoz Inc. (Patent Docs)

Roundup Ready Soybean: Infringement of US patent: Monsanto Co. et al. v. Slusser (Patent Docs)

Welchol (Colesevelam) – US:Impax Laboratories confirms patent challenge (SmartBrief)

Zyvox (Linezolid) – US: Pfizer sues Teva for Zyvox Patent, Eyeing Ratiopharm acquisition (Patentcircle)

 
 
 

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: